NCT Number: NCT02886637
Effects of Immune Function on Prognositic Outcome in Critical Ill Patients With Acinetobacter Baumannii Infection
The purpose of the present study is to evaluate the effects of immune function on prognositic outcome in critical ill patients with Acinetobacter baumannii infection.
Looking for future studies?
Notify MeKey information
Conditions
Age range
16 year–80 year
Sex eligibility
All sexes
Study type
Observational
About this study
This is a single-center, observational study. Patients with Acinetobacter baumannii infection in the intensive care unit of Zhongda Hospital were enrolled. We recorded the data of age, ICU admission diagnosis, underlying diseases, APACHE II score and infection site. Body temperature, heart rate, white blood cell counts, procalcitonin, C-reactive protein, SOFA score and the level of CD4+, CD8+, Th1, Th2 and HLA-DR in the blood measured by flow cytometry on the D1, D3 and D7 were also recorded.We can get the results of the change of immune function of critical ill patients after Acinetobacter baumannii infection. After compare the patients who die of survive at 28 day after infection, we can get the results of the relationship between the immune function and the outcome. We also can calculate the effect immune function on prognositic mortality in patients with Acinetobacter baumannii infection.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients admitted to ICU
- Infection with Acinetobacter baumannii
- Agree to participate the study
Exclusion criteria
- Age less than 16 years old or older than 80 years old
- pregnancy
- immunosuppression patients which include
- therapy 0.5mg/kg/day of prednisoneover(equivalent dose of other glucocorticoids) for at least 1 month within recent 3 month
- Cancer chemotherapy within recent 3 month
- Receive immunosuppression treatment because of solid organ transplant or Autoimmune diseases
- allogeneic bone marrow transplantation or allogeneic haematopoietic stem cell transplantation.
- HIV infection
Treatment and study plan
Primary outcomes
-
28 day mortality
Time frame: 28 day
Sponsors and collaborators
Lead sponsor
Southeast University, China
Other
Registry information
Important dates
- Study start
- 2015
- Primary completion
- 2016
- Study completion
- 2016
- First posted
- Sep 1, 2016
- Registry last updated
- Sep 1, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects
NCT03310463
Acinetobacter Baumannii Infection, Female Urogenital Diseases
Lakewood, Colorado, United States
View Trial DetailsEvaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy Subjects
NCT02971423
Acinetobacter Baumannii Infection, Infections
Melbourne, Victoria, Australia
View Trial DetailsCefiderocol vs Best Available Therapy for Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex Infections: A Target Trial Emulation
NCT07226557
Acinetobacter Baumannii Infection, Antimicrobial Drug Resistance
Bethesda, Maryland, United States
View Trial DetailsComparison of the Clinical Efficacy of Ampicillin/Sulbactam and Cefoperazone/Sulbactam Against Multidrug Resistant Acinetobacter Baumannii Infections in Critically Ill Patients
NCT07118384
Acinetobacter Baumannii Infection
Cairo, Egypt
View Trial Details